首页 / 院系成果 / 成果详情页

ADAM-17 is a poor prognostic indicator for patients with hilar cholangiocarcinoma and is regulated by FoxM1  期刊论文  

  • 编号:
    72d56a4d-6270-447a-9828-0cf6839ec5a4
  • 作者:
  • 语种:
    英文
  • 期刊:
    BMC CANCER ISSN:1471-2407 2018 年 18 卷 ; MAY 18
  • 收录:
  • 关键词:
  • 摘要:

    Background: A-disintegrin and metalloproteinases (ADAMs) are members of a family of multidomain transmembrane and secreted proteins. Specific ADAMs are upregulated in human cancers and correlated with tumor progression and poor outcome, but rarely studied in human hilar cholangiocarcinoma (HC). This study aimed to explore the expression profiles of ADAMs and their potential underlying mechanisms promoting cancer progression.
    Methods: mRNA expression of ADAM-9, - 10, - 11, - 12, - 15, - 17, - 28, and - 33 was analyzed in human hilar cholangiocarcinoma (HC) samples. Immunohistochemical (IHC) analysis was used to detect the expression of ADAM-10, - 17, - 28, and FoxM1 in HC. The regulation of ADAM-17 by FoxM1 and their functional study was investigated in vivo and in vitro.
    Results: ADAM-10, - 17, and - 28 were upregulated in tumors compared with matched non-cancerous tissues. IHC analysis revealed increased expression of ADAM-10, -17, and - 28 in HC cells, and ADAM17 seems to be an independent prognostic factor. ADAM-17 is regulated by FoxM1. A decrease in the expression of ADAM-17 by silencing FoxM1 led to an inhibition of cell proliferation, tumor growth, and the production of tumor necrosis factor alpha. IHC analysis showed co-expression of FoxM1 and ADAM-17 in HC specimens.
    Conclusions: The findings of the present study show an important role of the cross-talk among FoxM1, ADAM-17, and TNFa in HC development and progression.

  • 推荐引用方式
    GB/T 7714:
    Jiao Xiaodong,Yu Wenlong,Qian Jianxin, et al. ADAM-17 is a poor prognostic indicator for patients with hilar cholangiocarcinoma and is regulated by FoxM1 [J].BMC CANCER,2018,18.
  • APA:
    Jiao Xiaodong,Yu Wenlong,Qian Jianxin,Chen Ying,&Yu Guanzhen.(2018).ADAM-17 is a poor prognostic indicator for patients with hilar cholangiocarcinoma and is regulated by FoxM1 .BMC CANCER,18.
  • MLA:
    Jiao Xiaodong, et al. "ADAM-17 is a poor prognostic indicator for patients with hilar cholangiocarcinoma and is regulated by FoxM1" .BMC CANCER 18(2018).
  • 条目包含文件:
    文件类型:PDF,文件大小:
    正在加载全文
浏览次数:17 下载次数:0
浏览次数:17
下载次数:0
打印次数:0
浏览器支持: Google Chrome   火狐   360浏览器极速模式(8.0+极速模式) 
返回顶部